(5Z)-5-[(5-phenylfuran-2-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one | 851303-11-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: (5Z)-5-[(5-phenylfuran-2-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one
• CAS: 851303-11-2
• 化学式: C₁₄H₉NO₂S₂
• 分子量: 287.363
• InChiKey: LOXWDRJQRHUJBB-WQLSENKSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  99.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (5Z)-5-[(5-phenylfuran-2-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one 在 N,N-二异丙基乙胺 作用下， 以 乙醇 为溶剂， 反应 20.0h， 生成 (5Z,5Z’)-2,2-(heptane-1,7-diyldiimino)bis(1-(5-phenylfuran-2-yl)methylidene)-1,3-thiazol-4(5H)-one
  参考文献：
  名称：

  Design and synthesis of novel bis-thiazolone derivatives as micromolar CDC25 phosphatase inhibitors: Effect of dimerisation on phosphatase inhibition

  摘要：

  CDC25 phosphatases are involved in deregulated cell cycle progression and tumor development with poor prognosis. Among the most potent CDC25 inhibitors, quinonoid-based derivatives have been extensively studied. Dimerisation of heterocyclic quinones has led to IRC-083864, a bis-quinone compound with increased CDC25B inhibitory activity. Thirty-one bis-thiazolone derivatives were synthesized and assayed for CDC25 inhibitory activity. Most of the dimers displayed enhanced inhibitory activities with micromolar IC50 values lower than that observed for each thiazolone scaffold separately. Moreover, most of these compounds were selective CDC25 inhibitors. Dimer 40 showed an IC50 value of 2.9 mu M and could inhibit CDC25 activity without generating reactive oxygen species which is likely to occur with quinone-based inhibitors. Molecular docking studies suggested that the dimers could bind simultaneously to the active site and the inhibitor binding pocket. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.072
• 作为产物：
  描述：

  罗丹宁 、 5-苯基-2-糠醛 在 哌啶 作用下， 以 乙醇 为溶剂， 反应 12.0h， 生成 (5Z)-5-[(5-phenylfuran-2-yl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one
  参考文献：
  名称：

  Design and synthesis of novel bis-thiazolone derivatives as micromolar CDC25 phosphatase inhibitors: Effect of dimerisation on phosphatase inhibition

  摘要：

  CDC25 phosphatases are involved in deregulated cell cycle progression and tumor development with poor prognosis. Among the most potent CDC25 inhibitors, quinonoid-based derivatives have been extensively studied. Dimerisation of heterocyclic quinones has led to IRC-083864, a bis-quinone compound with increased CDC25B inhibitory activity. Thirty-one bis-thiazolone derivatives were synthesized and assayed for CDC25 inhibitory activity. Most of the dimers displayed enhanced inhibitory activities with micromolar IC50 values lower than that observed for each thiazolone scaffold separately. Moreover, most of these compounds were selective CDC25 inhibitors. Dimer 40 showed an IC50 value of 2.9 mu M and could inhibit CDC25 activity without generating reactive oxygen species which is likely to occur with quinone-based inhibitors. Molecular docking studies suggested that the dimers could bind simultaneously to the active site and the inhibitor binding pocket. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.072

文献信息

• [EN] RHODANINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] DERIVES DE RHODANINE ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2004043955A1

  公开（公告）日：2004-05-27

  This invention describes rhodanine derivatives and pharmaceutical compositions useful as inhibitors of ubiquitination. The compounds and compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. In particular, the compounds and compositions are useful for treating cell proliferative diseases such as cancers.

  这项发明描述了罗丹宁衍生物和制药组合物，可用作泛素化抑制剂。该发明的化合物和组合物可用作参与泛素化的生物体的生化途径的抑制剂。特别地，这些化合物和组合物可用于治疗细胞增殖性疾病，如癌症。
• Rhodanine derivatives and pharmaceutical compositions containing them
  申请人：Singh Rajinder

  公开号：US20060276520A1

  公开（公告）日：2006-12-07

  This invention describes rhodanine derivatives and pharmaceutical compositions useful as inhibitors of ubiquitination. The compounds and compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. In particular, the compounds and compositions are useful for treating cell proliferative diseases such as cancers.

  本发明描述了罗丹宁衍生物和药物组合物，用于抑制泛素化。本发明的化合物和组合物可用作生物体中泛素化涉及的生物化学通路的抑制剂。特别地，这些化合物和组合物可用于治疗细胞增殖性疾病，如癌症。
• Novel Antiviral Agents for Enveloped Viruses
  申请人：Lee Benhur

  公开号：US20120219613A1

  公开（公告）日：2012-08-30

  Provided herein are a series of arylmethylidene rhodanine derivatives having broad-spectrum antiviral activity against enveloped viruses, including but not limited to filoviruses, poxviruses, arenaviruses, bunyaviruses, paramyxoviruses, flaviviruses, influenza A, and HIV-1. The compounds act via a novel mechanism to disrupt viral membranes and inhibit viral attachment, fusion, and/or entry into host cells. The membrane disrupting activity of the compounds is selective for viral membranes relative to other biological membranes, making the compounds non-toxic to cells and host subjects.

  本文提供了一系列具有广谱抗病毒活性的芳基甲基亚胺基罗丹宁衍生物，可对包膜病毒产生作用，包括但不限于菲洛病毒、痘病毒、汉坦病毒、布尼亚病毒、副粘病毒、黄病毒、甲型流感病毒和HIV-1。这些化合物通过一种新颖的机制来破坏病毒膜并抑制病毒附着、融合和/或进入宿主细胞。这些化合物的膜破坏活性相对于其他生物膜具有选择性，使得这些化合物对细胞和宿主主体无毒性。
• RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS
  申请人：Singh Rajinder

  公开号：US20090137644A1

  公开（公告）日：2009-05-28

  This invention describes compounds and pharmaceutical compositions useful as inhibitors of ubiquitination. The compounds and compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. In particular, the compounds and compositions are useful for treating diseases caused by viruses such as poxviruses and retroviruses. The invention further provides for methods of treating smallpox, Herpes virus and HIV infection in patients using the compounds and compositions of the invention.

  这项发明描述了化合物和制药组合物，可用作泛素化抑制剂。该发明的化合物和组合物可用作生物体中泛素化参与的生化途径的抑制剂。特别是，该化合物和组合物可用于治疗由病毒引起的疾病，如痘病毒和逆转录病毒。该发明还提供了使用该化合物和组合物治疗天花、疱疹病毒和HIV感染患者的方法。
• RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS
  申请人：HADDACH Mustapha

  公开号：US20100331315A1

  公开（公告）日：2010-12-30

  The invention provides compounds that inhibit PIM kinases and/or CK2, and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, vascular disorders, pathogenic infections and certain immunological disorders.

  该发明提供了能够抑制PIM激酶和/或CK2的化合物以及含有这些化合物的组合物。这些化合物和组合物可用于治疗增殖性疾病如癌症，以及其他与激酶相关的疾病，包括炎症、疼痛、血管疾病、病原体感染和某些免疫性疾病。